An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis
Phase of Trial: Phase IV
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacokinetics
- 10 Jun 2017 Biomarkers information updated
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.